… systemic side effects at the doses most patients require, although the high doses used in
COPD has some systemic side effects and increases the risk of developing pneumonia. …

… Certainly some patients have developed cataracts while taking inhaled corticosteroids
but the combination of previous oral steroids and age is likely to have been at least in part …

… inhaled corticosteroids work in asthma, and much more data on the efficacy and safety of
inhaled corticosteroids … may even prevent patients from developing chronic airways obstruction. …

… adverse effects caused by the inhaled corticosteroids (ICSs). The … This review will explore
the risks for clinically significant … risk factor for development of fractures. They postulated that …

Inhaled corticosteroid (ICS) therapy carries less risk of complicating drug- or disease-related
morbidity and mortality than that associated with other antiasthmatic drugs such as …

… properties of an ideal inhaled corticosteroid for use in the … 10 years about the safety of
inhaled corticosteroids, and consider what … who develop adverse systemic effects from inhaled …

Inhaled corticosteroids (ICS) are now first‐line therapy for persistent asthma in children. The
major safety concerns of long‐term ICS therapy for childhood asthma are potential effects …

… Consequently, there is considerable interest in developing an ideal ICS that would … risk for
either upper airway or systemic side effects. Fortunately, a newly developed ICS, ciclesonide, …

… inhaled corticosteroids have an increased risk of fracture, particularly at the hip and spine.
However, this excess risk … to the underlying respiratory disease than to inhaled corticosteroid. …

… Bone density measurements suggest an increased risk of osteoporosis and … inhaled
corticosteroid therapy. There is also evidence of a long-term accumulative effect for the development …